Late-onset spinal form xanthomatosis without brain lesion: a case report

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disease caused by a deficiency in sterol 27-hydroxylase (CYP27A1), a key enzyme in the synthesis of chenodeoxycholic acid (CDCA), a primary bile acid. Deficiency of CYP27A1 and a lack of CDCA leads to the accumulation of cholesterol and cholestanol [1]. Typical clinical manifestations of CTX include bilateral cataracts and diarrhea in childhood [2] and progressive neurologic dysfunction (cerebral ataxia, paresis, dementia, low intelligence, and psychiatric disorder), tendon xanthoma, and atherosclerosis in adolescence and early adulthood [3]. Brain magnetic resonance imaging (MRI) typically reveals symmetrical lesions in the cerebellar white matter; however, white matter lesion restricted to the spinal cord are rare [4, 5].

In this paper, we report the case of a patient with predominantly spinal form of CTX, who had a clinical course, radiological pattern, and genetic background distinct from that of typical CTX.

A 77-year-old Japanese man with no particular medical history had observed thickening of the Achilles tendon bilaterally and patellar tendon enlargement (Fig. 1) from the age of 40. He reported paresthesia that began in the legs and later spread to the arms. He was admitted to Toho University Omori Medical Center for diagnosis a progressively unsteady gait from the age of 65 years, which was considered due to spinal ataxia. His father had died of lung cancer and his mother of renal failure. There was no family history (parents, siblings, or children) of CTX and his parents’ marriage was not consanguineous. He was born in Japan and worked as a public employee after graduating high school.

This spinal variant of CTX has a relatively mild course as compared with the classic form of CTX, which shows cerebellar involvement, dementia, tendon xanthoma formation, and peripheral neuropathy early in the disease process. Although neurological symptoms in CTX are often highly variable, most patients demonstrate cerebellar signs and mental retardation from a young age, as well as familial history, dementia, juvenile cataracts, and pyramidal tract lesion. However, in this case, it was important to exclude other diseases (Table 1) causing only myelopathy as no cerebral involvement was observed. The spinal cord pathology was different from that seen in multiple sclerosis, where a patchy, irregularly distributed involvement of the white matter is found, rather than a symmetrical distribution as seen in this case. Neuromyelitis optica is one of the differential diagnoses in this case; however, the anti-aquaporin 4 antibody tests were negative and optic neuritis was not observed. Hereditary spastic paraparesis is another differential diagnosis, and genetic testing would be needed if our case did not show any abnormal spine lesions [9].

The spinal form CTX without cerebral involvement is quite rare. Verrips et al. [4] reported seven Dutch patients from six families with a slowly progressing clinical course. Post-mortem examination of one of the patients showed extensive loss in the lateral and dorsal columns. The onset in these patients was between the ages of 20 and 35 years. Abe et al. [5] also reported a Japanese young-onset spinal form CTX. However, our patient showed late-onset, and did not show any cerebral involvement in brain MRI findings even at the age of 77 years old.

Early diagnosis of xanthomatosis is crucial as treatment with chenodeoxycholic acid can reduce plasma cholestanol level and may prevent disease progression [10], or even reverse some of the neurological disabilities [11]. A relatively high prevalence of CTX has been noticed in Japan, compared to that in other countries [12].

When we performed mutational analysis of all 9 exons of CYP27A1 in our Japanese patient with late-onset xanthomatosis with longitudinally extensive spinal cord lesion, we found one novel (Q85R) and one previously reported CTX-associated missense mutation (R405Q). None of the patient’s immediate family members showed similar symptoms, and his parents were not consanguineous. As they had not demonstrated a similar condition prior to their deaths, and as the patient’s siblings were not affected, we assume that the patient’s parents were each heterozygous for one of the two mutations.

Residue Q85 in CYP27A1 is a well-conserved amino acid, similar to R405, according to multiple sequence alignments analysis (Consurf Server http://​consurf.​tau.​ac.​il/​). The effect of the novel p.Q85R mutation on the function of CYP27A1 was predicted to be damaging as assessed a missence prediction tool, Polymorphism Phenotyping v2 (PolyPhen-2 http://​genetics.​bwh.​harvard.​edu/​pph2/​). Indeed, Q85 in CYP27A1 plays an important role in protein folding and binding with substrates, such as vitamin D₃ [13].

Considering the impact of p.Q85R and p.R405Q on clinical features, the compound heterozygosity of these two mutations may have resulted in a mild pathological change and late-onset of CTX, as compared to other missense mutations in CYP27A1. Moreover, p.R405Q may be associated with spinal form CTX, as a patient with homozygous mutations of p.R405Q presented with spinal form CTX [5].

Genetic testing in not readily available for diagnosing spinal form CTX; therefore, the presence of xanthoma in tendons and serum cholestenol levels should be assessed when the patient presents with chronic myelopathy.

CTX is treated with CDCA and/or competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase to reverse the metabolic defect and prevent neurological dysfunction. Previous reports have shown that this treatment results in reduction of the serum cholestenol level to less than 50 % of the pretreatment levels [5]. Lewis et al. [14] reported that mevinolin normalizes serum cholestenol level within 4 days and reduces the size of the xanthoma. However, whether these therapies will be effective for long-term prevention remains to be established.

Our results suggest that spinal form CTX should be considered in the differential diagnosis of chronic myelopathy, and clinicians should check for the presence of xanthomatosis in the tendons in such cases.

We obtained written informed consent from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.